May 12, 2026

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

The ASCO Post

May 12, 2026

Unique Phase I NSCLC Trial Sites Decreasing in United States

The number of unique clinical trial sites in the United States with phase I studies for patients with non–small cell lung cancer (NSCLC) decreased by 44% from 2020 to 2024, showing a significant conso...

The ASCO Post

May 11, 2026

New Generic Expands Glaucoma Options

Amneal Pharmaceuticals launches generic bimatoprost 0.01% in US

The Ophthalmologist

May 08, 2026

The Flu Vaccine Face-Off Ends in a Draw

Pragmatic cluster randomized crossover study found no statistically significant difference in laboratory-confirmed influenza during the 2023-2024 season

Conexiant

May 08, 2026

Phase 3 Win for TED Therapy

Amgen’s subcutaneous TEPEZZA meets phase 3 endpoints in thyroid eye disease

The Ophthalmologist

May 08, 2026

KEYNOTE-905: Perioperative Immunotherapy Regimen Active in Cisplatin-Ineligible MIBC

A perioperative regimen of enfortumab vedotin-ejfv plus pembrolizumab significantly improved survival and pathologic complete response rates compared to radical cystectomy alone in patients with muscl...

The ASCO Post

May 08, 2026

Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...

The ASCO Post

May 08, 2026

‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use

Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...

The ASCO Post

May 08, 2026

RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer

The treatment landscape for advanced pancreatic cancer is shifting. The common RAS mutation is now targetable and the race for the most effective inhibitor is heating up.  

The ASCO Post

May 06, 2026

Mass Spec Roundup: Protein Stress, Cannabis Chemistry and Sharks… 

From T cell dysfunction to shark vertebrae, mass spectrometry traces hidden chemistry across cells, crops, foods, and river systems 

The Analytical Scientist